Research Article | Open Access
Thomas Rehling, Anne Margareta Banghøj, Marie Hvelplund Kristiansen, Lise Tarnow, Stig Molsted, "Reduced Inspiratory Muscle Strength in Patients with Type 2 Diabetes Mellitus and Obstructive Sleep Apnoea", Journal of Diabetes Research, vol. 2017, Article ID 4121794, 6 pages, 2017. https://doi.org/10.1155/2017/4121794
Reduced Inspiratory Muscle Strength in Patients with Type 2 Diabetes Mellitus and Obstructive Sleep Apnoea
Background. Obstructive sleep apnoea (OSA) is related to type 2 diabetes (T2DM), and it may be associated with reduced inspiratory muscle strength (IMS). The aim of this study was to investigate the IMS in patients with T2DM, with or without OSA. Methods. Patients with T2DM with OSA () and without OSA () were included. The maximum IMS was tested using the POWERbreathe KH2 device. Reference IMS values were data calculated using an algorithm based on general populations and adjusted for age and gender. Results. There was no difference in IMS between the OSA group (median (range) 77 (35–124) cmH2O) and the non-OSA group (84 (33–122) cmH2O) (). The IMS values were reduced in the OSA group compared with the reference values (92.9 (62.3–100.0) cmH2O) (), whereas the non-OSA group did not have reduced IMS. When the IMS values of all T2DM patients were compared with reference values, the IMS values were 79 (33–124) cmH2O and 93.8 (62.3–102.4) cmH2O, respectively (). Conclusion. No difference in IMS between patients with T2DM with or without OSA was found. However, patients with T2DM and OSA had reduced IMS compared with age- and gender-matched references whereas the non-OSA group did not have reduced IMS.
Physical activity (PA) is a corner stone in the treatment of type 2 diabetes (T2DM). The effects of PA on patients with T2DM include an improved glycaemic control, reduced blood pressure, an improved blood lipid profile, and a reduced waist circumference [1–4]. Thus, PA may have the potential to decrease the risks of diabetic complications and mortality in patients with T2DM. As PA is an inexpensive and nonpharmacological treatment, the nature of PA further potentiates its therapeutic appeal. However, the level of PA in patients with T2DM remains reduced as compared to that in subjects without T2DM .
Patients with T2DM suffer from several complications and comorbidities; among them is obstructive sleep apnoea (OSA) . The prevalence of OSA among patients with T2DM has been reported to be 23–87%  which is in contrast to previous data from the general population reporting an OSA prevalence of 1–4% [7, 8]. Obstructive sleep apnoea is associated with an increased risk of cardiovascular disease . In addition, OSA is associated with excessive daytime sleepiness, mood changes, and cognitive dysfunction , all conditions that may impair the patients’ ability to increase their PA levels and make other important lifestyle changes. Chasens and Olshansky  found that in patients with T2DM, sleepiness was a daily burden and only a minimum number of activities was performed during daytime. These daily activities may also include PA; thus, OSA and excessive daytime sleepiness in people with T2DM may have important negative implications .
In a study from 2014, Chien et al. found reduced strength in m. diaphragma in patients with OSA without T2DM when compared with matched controls . In another study from 2016, Vranish and Bailey found that six-week inspiratory muscle training (IMT) in patients with OSA without T2DM was associated with positive effects on patient-reported sleep quality and blood pressure .
Whilst IMS may be reduced in patients with OSA without T2DM, it is unknown whether this association also is found in patients with OSA with concurrent T2DM. Accordingly, we tested the hypothesis that IMS in adults with T2DM without OSA is greater than that in adults with T2DM and OSA. The aim of this study was to compare IMS in patients with T2DM with and without OSA and to compare the patients’ IMS data with the IMS data in a gender- and age-matched reference population.
The data from the present study were obtained during the period of August 2015 to January 2017 as part of an ongoing study that aims to investigate the impact of continuous positive airway pressure (CPAP) treatment on arterial stiffness in patients with T2DM and newly diagnosed OSA.
Patients were recruited from the Department of Cardiology, Nephrology and Endocrinology, Nordsjællands Hospital, Denmark. In-home assessments of OSA were performed using an ApneaLink+® device. An apnoea-hypopnoea index (AHI) ≥ 15 was categorised as OSA. An AHI < 5 was categorised as non-OSA. The inclusion criteria were as follows: patients who are ≥18 years of age, who have T2DM (WHO criteria), who have an AHI ≥ 15 or AHI < 5 measured, and who have signed informed consent. The exclusion criteria were as follows: patients with contraindications to CPAP treatment, those having treatment with CPAP within the last six months prior to inclusion, those working in a transport-related industry, those having arterial fibrillation, those with major cardiovascular event within the last three months, those with heart failure (NYHA class III or IV), those with moderate-to-severe chronic obstructive lung disease, those with other sleep breathing disorders, those who had alcohol/drug abuse, those who are pregnant or nursing women, and those who are fertile women not using contraception.
Informed consent was obtained from all patients, and the local ethical committee approved the protocol (H-D-2008-124) in accordance with the 2000 Declaration of Helsinki as well as the Declaration of Istanbul 2008.
2.2. Inspiratory Muscle Strength
The IMS was determined using the POWERbreathe KH2 device, and the maximal inspiratory pressure (PIMAX) was reported in cmH2O. The participants were instructed to sit in a chair and close the nose using the thumb and index fingers. Patients were instructed in a warm-up exercise in which they completed approximately seven breaths against increasing resistance. The warm-up programme was then followed by a series of at least three measurements. If the last measurement was the highest, another measurement was performed until a lower value was measured to make sure that a maximum value was reached.
2.3. PIMAX Reference Values
The PIMAX reference values were calculated using the algorithm by Evans and Whitelaw . The algorithm is based on PIMAX data from previous studies, which, to the knowledge of the authors from this study, included data on more than 5000 subjects with and without diseases from general populations. Using reference values that were calculated is an alternative to the inclusion of an age- and gender-matched control group which was not included in this study. The strength of the present calculated reference values is the high number of individuals from general populations, where the algorithm is based on. The following equations were used: and . The algorithm is a linear regression reference equation as a function of age for adults aged up to 70 years . A reference value was created for every patient using the patient’s gender and age to match the patient.
The following equations were used to determine the lower limit of normal: and , also as reported by Evans and Whitelaw .
2.4. Blood Pressure, Pulse, and Glycaemic Control
Blood pressure and pulse were measured twice with a 10-minute rest allowed between each measure. The measured blood pressure with the lowest diastolic value and the lowest pulse were selected. Blood pressure was reported as mmHg and pulse as beats per minute. Glycaemic control was reported as haemoglobin A1c (HbA1c).
2.5. Physical Activity
An accelerometer (Actical, Philips Respironics, Bend, Oregon, USA) was used to measure PA. The device is an omnidirectional, waterproof, piezoelectric accelerometer. The size is 29 × 37 × 11 mm3 with a weight of 16 grams. The accelerometer registers vibrations during acceleration, which produce a proportional variable electrical voltage. We reported activity counts (AC) per day as reported previously . The accelerometer was placed on the patient’s ankle, and the patient was instructed to wear the accelerometer for one week, except whilst showering. Data from the accelerometer were downloaded, and mean activity counts per day were calculated based on at least five days of data registration.
2.6. Statistical Analyses
Statistical analyses were carried out using IBM® SPSS® Statistics 19. Data distributions were tested using Q-Q plots and histograms. The parametric unpaired Student’s t-test was used to test for differences in the two groups’ continuous variables with normal distributions.
The nonparametric unpaired Mann–Whitney U test was used to test for differences in continuous variables without normally distributed data. Differences in categorical variables were tested using a Chi-square or Fisher’s exact test. In order to adjust for differences between the groups, a multinomial linear regression analysis was performed. In the regression analysis, PIMAX was included as a dependent variable and age, gender, body mass index (BMI), HbA1c, and smoking were included as independent variables, and the results are presented as β and 95% confidence interval (CI) The participants’ characteristics are presented as the mean ± standard deviation (SD) or as median (range). All correlations were analysed using the Spearman rank correlation test for nonparametric analyses. All tests were two-tailed and significance was taken as being .
3.1. Characteristics of the Participants
Sixty-one participants were included in this study. The participants’ characteristics are presented in Table 1. The percentage of women was 18% in the OSA group and 33% in the non-OSA group (). The OSA group was on average 6.6 years older than the non-OSA group (). The BMI in the OSA group was 5.3 kg/m2 higher than that in the non-OSA group (), and HbA1c was 7 mmol/mol higher than that in the non-OSA group (). The OSA group had higher AHI values than the non-OSA group due to the nature of the protocol. There was no difference in blood pressure between the two groups. The percentages of current smokers were 6% in the OSA group and 25% in the non-OSA group ().
|Data are presented as the mean ± SD or as counts for the normally distributed variables. Nonnormally distributed data are presented as median (range). BP: blood pressure; AC: mean activity counts per 24 hours; BMI: body mass index; AHI: apnoea-hypopnoea index.|
3.2. Maximal Inspiratory Pressure
There was no difference between the OSA group’s PIMAX on 77 (35–124) cmH2O and the non-OSA group’s PIMAX on 84 (33–122) cmH2O ().
Whilst the PIMAX values in the OSA group were reduced compared with the PIMAX reference values (77 (35–124) cmH2O versus 92.9 (62.3–100.0) cmH2O, ), there was no difference between the non-OSA group and the respective PIMAX reference values (84 (33–122) cmH2O versus 94.2 (67.7–102.4) cmH2O, ) (see Figure 1). In all patients with T2DM, the median PIMAX value of 79 (33–124) cmH2O was different from the PIMAX reference value of 93.8 (62.3–102.4) cmH2O () (see Figure 2).
A negative correlation between PIMAX and age was found in the OSA group (, ), whereas no significant correlation was found between PIMAX and age in the non-OSA group (). The PIMAX was not associated with AHI in any of the groups (OSA , non-OSA ).
Six out of 61 patients (10%) had a PIMAX value below the lower limit of normal. The number of patients with a PIMAX value below the lower limit of normal was four out of 33 patients (12%) (OSA group) versus two out of 28 (7%) (non-OSA group) ().
3.3. Physical Activity
Due to missing data in nine participants, PA was analysed in 52 participants. There was no difference in PA level between the two groups. The correlation between PA and PIMAX in the OSA group was not significant (, ).
3.4. Body Mass Index
There was no significant association between BMI and PIMAX in the OSA group (, ) or in the non-OSA group (, ).
In the multinomial linear regression analysis adjusted for age, gender, BMI, HbA1c, and smoking, there was no significant association between OSA and PIMAX (β −9.4, 95% CI −26.6; 7.9, ).
The main finding of the present study was that there was no difference between PIMAX in patients with T2DM with or without OSA. However, when the two groups’ PIMAX values were compared with the reference values, the OSA group had reduced PIMAX, whereas PIMAX was not reduced in the non-OSA group.
Studies have shown that an increased age has a strong negative impact on PIMAX [14, 16–18]. Despite a higher age, impaired glycaemic control, and elevated BMI in the OSA group, the PIMAX was not reduced compared with that in the non-OSA group as anticipated. On the other hand, the non-OSA group included relatively more women and current smokers, and whilst women in general have lower PIMAX compared to men , smoking could also be anticipated to be associated with reduced PIMAX. Thus, several factors may have had influence on the result of the comparison between the two groups’ PIMAX. After confounder control in a multinomial linear regression analysis, there was no association between OSA and PIMAX. It is however important to note that the result of the regression analysis was achieved on the relatively low number of subjects in the study.
In another analysis with an adjustment for the age difference in the two groups, reference values were calculated to compare the patients with the control population . The OSA group’s PIMAX values were reduced compared with age- and gender-matched reference values, whereas the non-OSA group’s PIMAX values were not reduced. These results indicate that OSA is associated with reduced PIMAX.
The hypothesis was that PIMAX was impaired in the OSA group as a result of a potential chronic overload of m. diaphragma working against an obstructed upper airway which could lead to a negatively altered structure in the inspiratory muscle. Furthermore, the oxidative stress that often occurs in patients with OSA could also be expected to play a role in a potential negative impact on the IMS . The literature within the present research area is inconsistent, and the results vary from no difference in PIMAX to a difference between groups with or without OSA. Shepherd et al.  investigated the relation between inspiratory pump muscle force and OSA and found no difference in PIMAX in patients with and without OSA . However, the study by Shepherd et al. differs from the present study in terms of not having patients with T2DM included. Mezzanotte et al.  found reduced PIMAX in patients with OSA compared to age- and BMI-matched controls, even though the aim of the study was not to compare PIMAX between the two groups. Furthermore, one should notice that the study by Mezzanotte et al. included a relatively low number () of participants with OSA and 14 participants without OSA. A study by Chien et al.  found that people with OSA had reduced PIMAX compared to people without OSA. Fifteen participants with an AHI ≥ 30 were included. The control group was matched for age, weight, and height. Whether gender was equally distributed in the two groups is unknown, and it is therefore difficult to conclude that PIMAX was reduced as a result of OSA. The inconsistent results between the present and previous studies may be due to differences in patient cohorts.
The data from this study may suggest that T2DM per se was associated with reduced PIMAX, as one such result was found when the patient groups’ values were collapsed and compared with reference values. Type 2 diabetes may lead to reduced IMS as a result of the catabolic factors associated with T2DM. This catabolic effect on muscles is induced by more complications including neuropathy, insulin resistance, and chronic low-grade inflammation and may impact the diaphragm muscle negatively. Indeed, neuropathy may play a role in the reduced PIMAX, as a study  in patients with T2DM and autonomic neuropathy found reduced PIMAX in their participants. In the present study, most of the patients also suffered from OSA, and when previous and recent data are taken into account, it is difficult to see whether T2DM plays a significant role in the development of impaired IMS. Nevertheless, diabetic complications may affect the diaphragm muscle and reduce the inspiratory strength.
This study did not find any difference in PA between the OSA group and the non-OSA group, whereas a study from 2013 by Verwimp et al. found a negative correlation between PA and AHI . It is, however, important to note that the PA data in the present study had a relatively wide variation, maybe due to the method used.
Only a few studies have been made to investigate the outcome of IMT in patients with OSA. Vranish and Bailey found that daily IMT for six weeks reduced the blood pressure and the patients reported fewer nighttime arousals, compared to placebo IMT . In the study by Vranish and Bailey, patients with T2DM were however excluded, and it is unknown whether IMT could decrease AHI events in patients with T2DM. Our study is calling for new research to investigate the effect of IMT on patients with T2DM and OSA measured on AHI events and sleep quality.
The most important limitation of this study was the lack of a matched healthy control group. The use of reference values based on an algorithm does not replace a control group. However, the algorithm was developed on a relatively great number of subjects, a strength that may reduce biological variations in control groups. The study was also limited by a raw measure of PA and the placement of the accelerometer on the ankle. The placement on the ankle instead of the hip or thigh, which most often is used, was chosen as in Denmark, the common activity cycling may be underestimated as physical activity when accelerometers are worn on the hip or thigh . Furthermore, a relatively low number of participants warrant a more comprehensive study to confirm the present findings. The results may, however, suggest that the effects of IMT should be tested on OSA in patients with T2DM, as these patients had impaired IMS values compared to reference values whereas the non-OSA patients with T2DM did not.
In conclusion, there was no difference in the IMS between patients with T2DM with or without OSA. However, patients with T2DM and OSA had reduced IMS values compared with age- and gender-matched reference values.
This study was approved by the ethical committee (1-10-72-232-14).
Conflicts of Interest
The authors declare that they have no conflicts of interest.
For the expert support, the authors thank Linette Marie Kofod and Anna Maria Strømmen. This study was supported by unrestricted grants from the Region H Research Foundation, Nordsjællands Hospital.
- N. G. Boule, E. Haddad, G. P. Kenny, G. A. Wells, and R. J. Sigal, “Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus,” Journal of the American Medical Association, vol. 286, no. 10, pp. 1218–1227, 2001.
- A. Chudyk and R. J. Petrella, “Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis,” Diabetes Care, vol. 34, no. 5, pp. 1228–1237, 2011.
- N. J. Snowling and W. G. Hopkins, “Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis,” Diabetes Care, vol. 29, no. 11, pp. 2518–2527, 2006.
- D. E. Thomas, E. J. Elliott, and G. A. Naughton, “Exercise for type 2 diabetes mellitus,” The Cochrane Database of Systematic Reviews, vol. 3, article CD002968, 2006.
- S. Molsted, N. F. Johnsen, and O. Snorgaard, “Trends in leisure time physical activity, smoking, body mass index and alcohol consumption in Danish adults with and without diabetes: a repeat cross-sectional national survey covering the years 2000 to 2010,” Diabetes Research and Clinical Practice, vol. 105, no. 2, pp. 217–222, 2014.
- H. Storgaard, B. Mortensen, T. Almdal, M. Laub, and L. Tarnow, “At least one in three people with type 2 diabetes mellitus referred to a diabetes centre has symptomatic obstructive sleep apnoea,” Diabetic Medicine: A Journal of the British Diabetic Association, vol. 31, no. 11, pp. 1460–1467, 2014.
- P. Jennum and A. Sjol, “Epidemiology of snoring and obstructive sleep apnoea in a Danish population, age 30-60,” Journal of Sleep Research, vol. 1, no. 4, pp. 240–244, 1992.
- T. Young, M. Palta, J. Dempsey, J. Skatrud, S. Weber, and S. Badr, “The occurrence of sleep-disordered breathing among middle-aged adults,” The New England Journal of Medicine, vol. 328, no. 17, pp. 1230–1235, 1993.
- R. Billy Brissac, S. Phirai, L. Larifla et al., “Hypertension and cardiovascular risk associated with obstructive sleep apnea in adult in Guadeloupe (French West Indies),” Annales de Cardiologie et d'Angeiologie, vol. 64, no. 3, pp. 132–138, 2015.
- A. I. Sanchez, P. Martinez, E. Miro, W. A. Bardwell, and G. Buela-Casal, “CPAP and behavioral therapies in patients with obstructive sleep apnea: effects on daytime sleepiness, mood, and cognitive function,” Sleep Medicine Reviews, vol. 13, no. 3, pp. 223–233, 2009.
- E. R. Chasens and E. Olshansky, “The experience of being sleepy while managing type 2 diabetes,” Journal of the American Psychiatric Nurses Association, vol. 12, no. 5, pp. 272–278, 2006.
- M. Y. Chien, Y. T. Wu, P. L. Lee, Y. J. Chang, and P. C. Yang, “Inspiratory muscle dysfunction in patients with severe obstructive sleep apnoea,” The European Respiratory Journal, vol. 35, no. 2, pp. 373–380, 2010.
- J. R. Vranish and E. F. Bailey, “Inspiratory muscle training improves sleep and mitigates cardiovascular dysfunction in obstructive sleep apnea,” Sleep, vol. 39, no. 6, pp. 1179–1185, 2016.
- J. A. Evans and W. A. Whitelaw, “The assessment of maximal respiratory mouth pressures in adults,” Respiratory Care, vol. 54, no. 10, pp. 1348–1359, 2009.
- D. John and P. Freedson, “ActiGraph and actical physical activity monitors: a peek under the hood,” Medicine and Science in Sports and Exercise, vol. 44, Supplement 1, no. 1, pp. S86–S89, 2012.
- R. Gosselink, J. De Vos, S. P. van den Heuvel, J. Segers, M. Decramer, and G. Kwakkel, “Impact of inspiratory muscle training in patients with COPD: what is the evidence?” The European Respiratory Journal, vol. 37, no. 2, pp. 416–425, 2011.
- G. L. Ruppel and P. L. Enright, “Pulmonary function testing,” Respiratory Care, vol. 57, no. 1, pp. 165–175, 2012.
- I. M. Sclauser Pessoa, V. Franco Parreira, G. A. Fregonezi, A. W. Sheel, F. Chung, and W. D. Reid, “Reference values for maximal inspiratory pressure: a systematic review,” Canadian Respiratory Journal, vol. 21, no. 1, pp. 43–50, 2014.
- L. Lavie, “Obstructive sleep apnoea syndrome – an oxidative stress disorder,” Sleep Medicine Reviews, vol. 7, no. 1, pp. 35–51, 2003.
- K. L. Shepherd, C. M. Jensen, K. J. Maddison, D. R. Hillman, and P. R. Eastwood, “Relationship between upper airway and inspiratory pump muscle force in obstructive sleep apnea,” Chest, vol. 130, no. 6, pp. 1757–1764, 2006.
- W. S. Mezzanotte, D. J. Tangel, and D. P. White, “Waking genioglossal electromyogram in sleep apnea patients versus normal controls (a neuromuscular compensatory mechanism),” The Journal of Clinical Investigation, vol. 89, no. 5, pp. 1571–1579, 1992.
- D. M. Kaminski, B. D. Schaan, A. M. da Silva, P. P. Soares, and P. D. Lago, “Inspiratory muscle training in patients with diabetic autonomic neuropathy: a randomized clinical trial,” Clinical Autonomic Research: Official Journal of the Clinical Autonomic Research Society, vol. 25, no. 4, pp. 263–266, 2015.
- J. Verwimp, L. Ameye, and M. Bruyneel, “Correlation between sleep parameters, physical activity and quality of life in somnolent moderate to severe obstructive sleep apnea adult patients,” Sleep & Breathing = Schlaf & Atmung, vol. 17, no. 3, pp. 1039–1046, 2013.
- B. Herman Hansen, I. Børtnes, M. Hildebrand, I. Holme, E. Kolle, and S. A. Andersen, “Validity of the ActiGraph GT1M during walking and cycling,” Journal of Sports Science, vol. 32, no. 6, pp. 510–516, 2014.
Copyright © 2017 Thomas Rehling et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.